MYGN
Myriad Genetics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 0
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MYGN
Myriad Genetics, Inc.
A leader in genetic testing and precision medicine
322 North 2200 West, Salt Lake City, UT 84116
--
Myriad Genetics, Inc., is a Delaware corporation. The company is a leading genetic testing and precision medicine company dedicated to promoting the health and well-being of all people. The company provides insights that help people take control of their health and enable health care providers to better detect, treat and prevent disease. The company develops and provides tests that help assess the risk of disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and reduce healthcare costs.
Earnings Call
Q1/2025
Estimate EPS-0.05
Actual EPS-0.03
Estimate Revenue200.51M
Actual Revenue195.90M
Myriad Genetics Q1 2025: Contradictions Unraveled on GeneSight Performance, Oncology Focus, and EMR Integration
May 13,2025 04:41
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.01
Actual EPS0.05
Estimate Revenue202.30M
Actual Revenue213.10M
Myriad Genetics Q2 2025: Unraveling Contradictions in Strategic Focus, GeneSight Performance, and Oncology Growth
Aug 06,2025 04:24
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.01
Actual EPS0
Estimate Revenue205.14M
Actual Revenue205.70M
Myriad's Q3 2025: Contradictions Emerge on Growth Strategy, R&D Allocation, and Market Penetration
Nov 04,2025 12:06
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
MYGN has released its 2025 Q3 earnings. EPS was reported at 0, versus the expected -0.01, beating expectations. The chart below visualizes how MYGN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MYGN has released its 2025 Q3 earnings report, with revenue of 205.70M, reflecting a YoY change of -3.56%, and net profit of -27.40M, showing a YoY change of -23.98%. The Sankey diagram below clearly presents MYGN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
